arrow
B

Birgit I. Lissenberg-Witte

isglobal
H指数:53
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab

多发性硬化患者接受奥瑞利珠单抗延长间隔给药后CD19+ B细胞再生的个体差异

2026-07-070
OA
Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/refractory acute myeloid leukemia
2026-03-011
PRE
Impacts of a city-wide 30 km/h speed limit intervention on physical activity, child safety and social behaviours: a natural experimental study in Amsterdam, the Netherlands

城市范围内30公里/小时限速干预措施对体力活动、儿童安全和社会行为的影响:荷兰阿姆斯特丹的一项自然实验研究

2026-01-011
OAAI
Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea

β地中海贫血患者接种COVID-19疫苗后的体液和细胞免疫应答

2025-11-280
OAAI
Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS) – an Individual Participant Data Meta-Analysis

利妥昔单抗相较于奥瑞珠单抗在多发性硬化中的非劣效性(ROC-MS)——一项个体参与者数据meta分析

2025-11-110
OAAI
CtDNA-guided de-escalation of adjuvant chemotherapy in stage III colon cancer: early model-based evaluation of cost-effectiveness

CtDNA指导下的辅助化疗降级治疗在III期结肠癌中的应用:基于模型的早期成本效益评估

2025-11-060
OA
T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines
2025-11-010
OAAI
Real-world efficacy and safety of immunochemotherapy in cold agglutinin-mediated autoimmune haemolytic anaemia

冷凝集素介导的自身免疫性溶血性贫血中免疫化疗的疗效与安全性

2025-10-220
OAAI
Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS)

卡铂与顺铂的生存结局以及COVID-19对铂类药物选择的影响:一项针对小细胞肺癌患者的荷兰全国登记研究(CACIS)

2025-10-020
PRE
COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study

COVID-19疫苗在血液系统恶性肿瘤患者中的有效性:一项全国性队列研究

2025-10-010
OAAI
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe

欧洲接受CAR T细胞疗法治疗的血液恶性肿瘤患者的患者报告结局

2025-09-260
OAAI
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)

血清神经丝蛋白轻链和胶质纤维酸性蛋白在稳定型多发性硬化(DOT-MS)中停用一线疾病修饰疗法后检测疾病活动的可靠性

2025-07-230
OAAI
Efficacy and Budget Impact of a Tailored Psychological Intervention Program Targeting Cancer Patients With Adjustment Disorder: A Randomised Controlled Trial

针对伴有适应障碍的癌症患者的个性化心理干预方案的疗效与预算影响:一项随机对照试验

2025-03-010
OAAI
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
2025-03-010
PRE